RxDoctor Payments Data

Daniel Fields, MD

Internal Medicine · Miami, FLNPI 1639197098

Payments from drug & device makers

$1,345in general payments, 2019–2025

Across 68 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$511
  • AstraZeneca$225
  • Novo Nordisk$163
  • GSK$119
  • Lilly USA, LLC$107
  • Abbott$78
  • plus $141 from 5 others

What the payments were for

  • Food & beverage$1,345100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen31$511
AstraZeneca9$225
Novo Nordisk8$163
GSK5$119
Lilly USA, LLC6$107
Abbott3$78
Pfizer2$49
AbbVie1$32
Kowa Pharmaceuticals America, Inc.1$32
IBSA Pharma Inc.1$18
Nalpropion Pharmaceuticals LLC1$11

How this compares

$1,345 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$33,534
Medicare patients
71
Services billed
302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WakixPitolisant Hcl11$172,714
MounjaroTirzepatide81$93,849
OzempicSemaglutide45$51,100
Rosuvastatin Calcium104$1,512
Telmisartan16$1,427
Nifedipine ErNifedipine12$1,286
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen25$1,131
Albuterol Sulfate HfaAlbuterol Sulfate18$784
Nebivolol Hcl12$738
Metoprolol Succinate49$696
Alprazolam100$632
Gabapentin30$613
Valsartan14$569
Esomeprazole Magnesium16$515
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine20$487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$107$93,84981 claims
Novo NordiskOzempic$163$51,10045 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →